AbCellera reports Q3 2026 results, highlights ABCL635 Phase 2 and $200M raise
Positive Phase 2 data for menopause drug ABCL635 and a $200 million share offering anchor the quarter, alongside Phase 1 results for ABCL575 that will not advance past that stage.
SEC filing